feed,title,long_url,short_url
Benzinga,"EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023",https://benzinga.com/general/biotech/22/11/29722394/exclusive-sab-biotherapeutics-posts-wider-quarterly-loss-cash-runway-expected-into-mid-2023,https://bit.ly/3tx3kHi
Benzinga,"Exicure Flags Bankruptcy Concerns, Shares Fall",https://benzinga.com/general/biotech/22/11/29722603/exicure-flags-bankruptcy-concerns-shares-fall,https://bit.ly/3UO6h1E
